94MO Quality of life (QoL) with fulvestrant (FUL)/palbociclib (PAL) versus FUL/placebo (PBO) in postmenopausal women with hormone receptor (HR)+/HER2- endocrine sensitive advanced breast cancer (ABC): Results from GEICAM/2014-12 (FLIPPER) study.

Authors :: Tibau, A.
Martinez, M.T.
Ramos, M.
De la Cruz-Merino, L.
Santaballa, A.
Connor, M. O'
Martinez-Jañez, N.
Moreno, F.
Fernandez-Perez, I.
Virizuela, J.A.
Alarcón, J.
de la Haba-Rodríguez, J.
Sánchez-Rovira, P.
Albacar, C.R.
Bueno, C.
Kelly, C.
Casas, M.
Bezares, S.
Rosell, L.
Albanell, J.
Source :: Annals of Oncology. 2021 Supplement 2, Vol. 32, pS63-S63. 1p.
Publication Year :: 2021

Subjects :: *HORMONE receptor positive breast cancer
*POSTMENOPAUSE
*DRUG efficacy

Full Text Access

Tools